By inhibiting the activity of CDK4 and CDK6, it controls the proliferation of tumor cells.
Abemaciclib is a CDK4/6 inhibitor that has a therapeutic effect on breast cancer. The main mechanism is to control the proliferation of tumor cells by inhibiting the activity of two key protein kinases, CDK4 and CDK6. Cell cycle regulation depends on the interaction between Cyclin-dependent kinases (CDKs) and their ligands, cyclins. CDK4 and CDK6 form a complex with cyclinD and play an important role in the transition from G1 phase to S phase. The complex promotes cells to enter the DNA synthesis stage and promotes cell proliferation.